Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Elizabeth Katherine Lee, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Konstantinopoulos PA, Lee EK, Xiong N, Krasner C, Campos S, Kolin DL, Liu JF, Horowitz N, Wright AA, Bouberhan S, Penson RT, Yeku O, Bowes B, Needham H, Hayes M, Sawyer H, Polak M, Shea M, Cheng SC, Castro C, Matulonis UA. A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial Cancer. J Clin Oncol. 2022 Sep 29; JCO2200628. PMID: 36174113.
    Citations: 1     Fields:    
  2. Konstantinopoulos PA, Gockley AA, Xiong N, Krasner C, Horowitz N, Campos S, Wright AA, Liu JF, Shea M, Yeku O, Castro C, Polak M, Lee EK, Sawyer H, Bowes B, Moroney J, Cheng SC, Tayob N, Bouberhan S, Spriggs D, Penson RT, Fleming GF, Nucci MR, Matulonis UA. Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial Cancer. JAMA Oncol. 2022 09 01; 8(9):1317-1322. PMID: 35900726; PMCID: PMC9335244.
    Citations:    Fields:    
  3. Konstantinopoulos PA, da Costa AABA, Gulhan D, Lee EK, Cheng SC, Hendrickson AEW, Kochupurakkal B, Kolin DL, Kohn EC, Liu JF, Stover EH, Curtis J, Tayob N, Polak M, Chowdhury D, Matulonis UA, Färkkilä A, D'Andrea AD, Shapiro GI. A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun. 2021 09 22; 12(1):5574. PMID: 34552099; PMCID: PMC8458434.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  4. Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021 01; 160(1):322-332. PMID: 33160694.
    Citations: 5     Fields:    Translation:Humans
  5. Lee EK, Xiong N, Cheng SC, Barry WT, Penson RT, Konstantinopoulos PA, Hoffman MA, Horowitz N, Dizon DS, Stover EH, Wright AA, Campos SM, Krasner C, Morrissey S, Whalen C, Quinn R, Matulonis UA, Liu JF. Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78. PMID: 32771276.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  6. Chapel DB, Lee EK, Da Silva AFL, Teschan N, Feltmate C, Matulonis UA, Crum CP, Sholl LM, Konstantinopoulos PA, Nucci MR. Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021 03; 34(3):613-626. PMID: 32759977.
    Citations: 1     Fields:    Translation:Humans
  7. Lee EK, Matulonis UA. PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. Cancers (Basel). 2020 Jul 25; 12(8). PMID: 32722408; PMCID: PMC7465003.
    Citations: 12     
  8. Lee EK, Konstantinopoulos PA. PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers. Ther Adv Med Oncol. 2020; 12:1758835920944116. PMID: 32782491; PMCID: PMC7383615.
    Citations: 10     
  9. Lee EK, Esselen KM, Kolin DL, Lee LJ, Matulonis UA, Konstantinopoulos PA. Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. JCO Precis Oncol. 2020; 4:736-742. PMID: 32704608.
    Citations: 1     Fields:    
  10. Lee EK, Matulonis UA. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. Expert Opin Emerg Drugs. 2020 06; 25(2):165-188. PMID: 32569489.
    Citations: 5     Fields:    Translation:Humans
  11. Konstantinopoulos PA, Cheng SC, Wahner Hendrickson AE, Penson RT, Schumer ST, Doyle LA, Lee EK, Kohn EC, Duska LR, Crispens MA, Olawaiye AB, Winer IS, Barroilhet LM, Fu S, McHale MT, Schilder RJ, Färkkilä A, Chowdhury D, Curtis J, Quinn RS, Bowes B, D'Andrea AD, Shapiro GI, Matulonis UA. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968. PMID: 32553118.
    Citations: 35     Fields:    Translation:HumansCTClinical Trials
  12. Gulhan DC, Garcia E, Lee EK, Lindemann NI, Liu JF, Matulonis UA, Park PJ, Konstantinopoulos PA. Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer. JCO Precis Oncol. 2020; 4:492-497. PMID: 32494760; PMCID: PMC7269172.
    Citations: 3     Fields:    
  13. Lee EK, Tan-Wasielewski Z, Aghajanian C, Coleman RL, Curtis J, Hirsch MS, Matulonis UA, Cantley LC, Mills GB, Doyle LA, Liu JF. Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546. PMID: 32083163; PMCID: PMC7021536.
    Citations: 3     
  14. Lee EK, Tan-Wasielewski Z, Matulonis UA, Birrer MJ, Wright AA, Horowitz N, Konstantinopoulos PA, Curtis J, Liu JF. Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122. PMID: 31467965.
    Citations: 4     
  15. Lee EK, Konstantinopoulos PA. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer. Trends Cancer. 2019 09; 5(9):524-528. PMID: 31474356.
    Citations: 26     Fields:    Translation:HumansCells
  16. Veneris JT, Lee EK, Goebel EA, Nucci MR, Lindeman N, Horowitz NS, Lee L, Raut CP, Crotzer D, Matulonis U, Konstantinopoulos PA, Campos S. Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478. PMID: 30935717.
    Citations: 8     Fields:    Translation:Humans
  17. Lee EK, Liu JF. Antibody-drug conjugates in gynecologic malignancies. Gynecol Oncol. 2019 06; 153(3):694-702. PMID: 30929824.
    Citations: 8     Fields:    Translation:Humans
  18. Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA. POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. Gynecol Oncol Rep. 2019 May; 28:15-17. PMID: 30733993; PMCID: PMC6357694.
    Citations: 4     
  19. Saiki CB, Waldfogel JM, Lee EK, Smith TJ. Strategies for Addressing Cancer Patients' Complaints of Fatigue. Oncology (Williston Park). 2017 11 15; 31(11):808-12. PMID: 29181836.
    Citations:    Fields:    Translation:Humans
  20. Lawrence D, Shah AK, Lee EK, Conway SJ, Ramkumar MK, James HJ, Queale WS, Keller SC, Biddison EL, Gregg PC, Ashar BH, Desai SV, Brotman DJ, Berry SA. Primary Care Provider Preferences for Communication with Inpatient Teams: One Size Does Not Fit All. J Hosp Med. 2018 03 01; 13(3):177-178. PMID: 29154380.
    Citations: 2     Fields:    Translation:Humans
  21. Yadav D, Lee E, Papachristou GI, O'Connell M. A population-based evaluation of readmissions after first hospitalization for acute pancreatitis. Pancreas. 2014 May; 43(4):630-7. PMID: 24681876.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  22. Yazji I, Sodhi CP, Lee EK, Good M, Egan CE, Afrazi A, Neal MD, Jia H, Lin J, Ma C, Branca MF, Prindle T, Richardson WM, Ozolek J, Billiar TR, Binion DG, Gladwin MT, Hackam DJ. Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signaling. Proc Natl Acad Sci U S A. 2013 Jun 04; 110(23):9451-6. PMID: 23650378.
    Citations: 85     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lee's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (114)
Co-Authors (30)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.